1 November 1997 in European Journal of Biochemistry
In this paper, we show that P‐glycoprotein contains two distinct sites for drug binding and transport, and that, unexpectedly, these sites interact in a positively cooperative manner. The kinetics of transport of rhodamine 123 and Hoechst 33342 in isolated P‐glycoprotein‐rich plasma membrane vesicles from Chinese hamster ovary CHRB30 cells were followed by continuous fluorescence monitoring. Each substrate stimulated P‐glycoprotein‐mediated transport of the other. Colchicine and quercetin stimulated rhodamine 123 transport and inhibited Hoechst 33342 transport. In contrast, anthracyclines such as daunorubicin and doxorubicin stimulated Hoechst 33342 transport and inhibited rhodamine 123 transport. Vinblastine, actinomycin D, and etoposide inhibited transport of both dyes. The results are consistent with a functional model of P‐glycoprotein containing at least two positively cooperative sites (H site and R site) for drug binding and transport. This model is consistent with earlier observations of competitive and non‐competitive effects of P‐glycoprotein substrates and chemosensitizers. Such a two‐site model may be fundamental to multidrug transport by P‐glycoprotein, and it may be a feature common to other ATP‐dependent transporters belonging to the ATP‐binding cassette superfamily.
1 February 2001 in Journal of Neurochemistry
30 June 2017 in Nature Microbiology
TDThomas F. Durand-Réville
+20
1 February 1999 in European Journal of Biochemistry
1 March 2015 in Antimicrobial Agents and Chemotherapy
Sulbactam is a class A β-lactamase inhibitor with intrinsic whole-cell activity against certain bacterial species, including Acinetobacter baumannii . The clinical use of sulbactam for A. baumannii infections is of interest due to increasing multidrug resistance in this pathogen. However, the molecular drivers of its antibacterial activity and resistance determinants have yet to be precisely defined. Here we show that the antibacterial activities of sulbactam vary widely across contemporary A. baumannii clinical isolates and are mediated through inhibition of the penicillin-binding proteins (PBPs) PBP1 and PBP3, with very low frequency of resistance; the rare pbp3 mutants with high levels of resistance to sulbactam are attenuated in fitness. These results support further investigation of the potential clinical utility of sulbactam.
1 February 1997 in Biochemical Pharmacology